Honghao Wang

Honghao Wang

Auto-generated profile, based on publicly available information

Honghao Wang

Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
MYMeiwen Yuan
Meiwen Yuan
XZXuelian Zhao
Xuelian Zhao
HWHonghao Wang
Honghao Wang
SHShangying Hu
Shangying Hu
FZFanghui Zhao
Fanghui Zhao
Background: There are no studies extrapolating the incidence and mortality of cervical cancer in China by comparing incidence and deaths pattern between geographic and age groups. Methods: We applied age-period-cohort models to assess region-level trends in incidence and mortality from 2006 to 2016, with piecewise linear regression in a Bayesian framework to predict these trends to 2030. Results: Between 2006 and 2016, age-standardized incidence rates (ASIR) for females aged 15 to 84 years increased by 3.7% (95% confidence interval, 3.1%–4.3%) annually from 11.01 to 16.41 per 100,000 females in China. In the 25 to 39 age groups, the incidence rates decreased in urban regions and inversely increased in rural regions. The age-standardized mortality rates (ASMR) increased from 3.18 to 4.83, with annual increases of about 3.6% (1.5%–5.8%). From 2017 to 2030, the ASIR is expected to increase from 17.13 (15.91–18.46) to 23.22 (20.02–27.01) by 2.5% per year (P < 0.05). Meanwhile, the average age at diagnosis is predicted to grow from 53.1 to 60.5 years. In the 15 to 54 age groups, the incidence rates decreased in urban regions but increased in rural regions. The ASMR is expected to increase consistently from 4.82 (4.38–5.31) to 9.13 (7.35–11.39) by 5.0% per year (P < 0.05). Conclusions: Cervical cancer incidence and mortality rates are projected to increase in China. In addition, the urban–rural incidence gap is estimated to widen further among young women. Impact: Cervical cancer prevention should consider the trend and diversity in incidence patterns between urban and rural regions.

10 March 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
RDRufei Duan
Rufei Duan
KXKunpeng Xu
Kunpeng Xu
LHLiuye Huang
Liuye Huang
MYMeiwen Yuan
Meiwen Yuan
HWHonghao Wang
Honghao Wang
FZFanghui Zhao
Fanghui Zhao
Background: Information on temporal trends of cancer attributable to human papillomavirus (HPV) in China is limited. Methods: Cancer incidence and mortality during 2007 to 2015 were extracted from the Chinese Cancer Registry Annual Report and the national population from the National Bureau of Statistics. HPV-attributable cancer burden and the average annual percentage change during 2007 to 2015 were estimated and cancer burden during 2016 to 2030 was projected. Results: HPV-attributable cancer cases have increased by 3.8% [95% confidence interval (CI), 2.9%–4.8%] annually from 85,125 to 113,558 and age-standardized incidence rate (ASIR) rose by 3.0% (95% CI, 2.5%–3.5%) from 4.67 to 5.83 per 100,000 persons during 2007 to 2015. Cervical, female anal, and vulva cancer cases have increased by 3.8% (95% CI, 2.8%–4.7%), 6.5% (95% CI, 1.2%–12.2%), and 3.7% (95% CI, 1.6%–5.8%) per year. Male anal and oropharyngeal cancer cases have elevated by 7.5% (95% CI, 2.8%–12.5%) and 4.4% (95% CI, 2.4%–6.3%) annually. The increases of cervical and anal cancer were most rapid among those aged 50 and older. HPV-attributable cancer deaths and mortality rate have risen by 4.7% (95% CI, 2.9%–6.7%) and 3.3% (95% CI, 0.9%–5.8%) respectively. HPV-attributable cancer cases and ASIR are projected to reach 214,077 and 9.35 of 100,000 persons by 2030 respectively, with 87.7% being cervical cancer, and anal cancer cases are expected to triple. Conclusions: HPV-attributable cancer burden has largely increased in the past and will keep rising for the next decade. Cervical cancer control should be the priority and anal cancer prevention should be addressed. Impact: This study supplies fundamental evidence for policy-making on HPV-attributable cancer control.

12 April 2023
Verified
Other
Open access
MYMeiwen Yuan
Meiwen Yuan
XZXuelian Zhao
Xuelian Zhao
HWHonghao Wang
Honghao Wang
SHShangying Hu
Shangying Hu
FZFanghui Zhao
Fanghui Zhao
Figure S4 age-period-cohort effect on cervical cancer mortality rates in China between 2006 to 2016.

12 April 2023
Verified
Other
Open access
MYMeiwen Yuan
Meiwen Yuan
XZXuelian Zhao
Xuelian Zhao
HWHonghao Wang
Honghao Wang
SHShangying Hu
Shangying Hu
FZFanghui Zhao
Fanghui Zhao
Table S1 shows average age and standardized average age at diagnosis for cervical cancer between 2006 to 2030.

12 April 2023
Verified
Other
Open access
MYMeiwen Yuan
Meiwen Yuan
XZXuelian Zhao
Xuelian Zhao
HWHonghao Wang
Honghao Wang
SHShangying Hu
Shangying Hu
FZFanghui Zhao
Fanghui Zhao
Figure S2 shows trends for deaths during 2006−2016 and predicted from 2017 to 2030 in China.

12 April 2023
Verified
Other
Open access
MYMeiwen Yuan
Meiwen Yuan
XZXuelian Zhao
Xuelian Zhao
HWHonghao Wang
Honghao Wang
SHShangying Hu
Shangying Hu
FZFanghui Zhao
Fanghui Zhao
Figure S3 shows age-period-cohort effect on cervical cancer incidence rates in China between 2006 to 2016.